Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function

Psychopharmacology

Volumn 184, Issue 2, 2006, Pages 190-200

  Duncan, Gary E ^a   Moy, Sheryl S ^a   Lieberman, Jeffery A ^a   Koller, Beverly H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acoustic startle; Antipsychotic; Mouse model; NMDA receptor; Prepulse inhibition; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUETIAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHANNEL GATING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENETIC MODEL; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SENSORIMOTOR FUNCTION; SPECIES COMPARISON; STARTLE REFLEX; WILD TYPE;

ACOUSTIC STIMULATION; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HALOPERIDOL; HIPPOCAMPUS; HISTAMINE ANTAGONISTS; IMIPRAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SEX CHARACTERISTICS; STARTLE REACTION;

EID: 30544437565     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0214-1     Document Type: Article

References (50)

1. Acri JB, Morse DE, Popke EJ, Grunberg NE (1994) Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology 114:369-374
2. Angrist B, Rotrosen J, Gershon S (1980) Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 67:31-38
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234
4. Arvanov VL, Wang RY (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289:1000-1006
5. Bai F, Li X, Clay M, Lindstrom T, Skolnick P (2001) Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 70:187-192
6. Bakshi VP, Geyer MA (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201
7. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
8. Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, Kew JNC (2002) Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22:6713-6723
9. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234-258
10. Brody SA, Conquet F, Geyer MA (2003) Disruption of prepulse inhibition in mice lacking mGluRl. Eur J Neurosci 18:3361-3366
11. Brody SA, Conquet F, Geyer MA (2004) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172:187-195
12. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS (1962) Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl) lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II - symbolic and sequential thinking. Arch Gen Psychiatry 6:79-85
13. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74
14. David DJP, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373-382
15. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812:65-75
16. Duncan GE, Miyamoto S, Gu HB, Lieberman JA, Koller BH, Snouwaert JN (2002) Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 951:166-176
17. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (2000) Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293:8-14
18. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, Snouwaert JN, Koller BH (2004) Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153:507-519
19. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154
20. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27
21. Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215
22. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482
23. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617
24. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36
25. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236
26. Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557-566
27. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
28. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872
29. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
30. Lahti AC, Weiler MA, Tamara MB, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467
31. Leeson PD, Iversen LL (1994) The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem 37:4053-4067
32. Lieberman JA, Kane JM, Alvir JAJ (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415-433
33. Lipina T, Labrie V, Weiner I, Roder J (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179:54-67
34. Luby ED, Cohen BD, Rosenbaum G, Gottilieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug-sernyl. Arch Neurol Psych 81:363-369
35. Malhotra AK, Finals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150
36. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition - the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
37. Mansbach RS, Carver J, Zorn SH (2001) Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 69:535-542
38. McCaughran J, Mahjubi E, Decena E, Hitzemann R (1997) Genetics, haloperidol induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology 134:131-139
39. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T (2001) Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit. J Neurosci 21:750-757
40. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436
41. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z, Brunner D (2001) The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology 156:284-290
42. Ouagazzal AM, Jenck F, Moreau JL (2001) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156:273-283
43. Paylor R, Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 132:169-180
44. Schreiber R, Dalmus M, De Vry J (2002) Effects of alpha(4)/beta (2)- and alpha(7)-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 159:248-257
45. Simon VM, Parra A, Minarro J, Arenas MC, Vinader-Caerols C, Aguilar MA (2000) Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 10:159-164
46. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998) Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacologia 140:75-80
47. Swerdlow NR, Bakshi VP, Geyer MA (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290-1299
48. Tada M, Shirakawa K, Matsuoka N, Mutoh S (2004) Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology 176:94-100
49. Tsai G, Pinchen Y, Chung L-C, Lange N, Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089
50. Zhang W, Bymaster FP (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors. Psychopharmacology 141:267-278